Related Experiment Video
Updated: Jul 29, 2026

12:17
An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
Published on: May 8, 2017
12.4K
Jacqueline du Pré and her alternative diagnosis
Takahiro Mezaki1, Kanako Namekawa2
1Department of Neurology, Sakakibara Hakuho Hospital, Sakakibara-cho, Tsu City, Mie 514-1251, Japan.
Medical Hypotheses
|September 23, 2019
Summary
The diagnosis of multiple sclerosis (MS) for cellist Jacqueline du Pré is questioned due to atypical symptoms and progression. Alternative diagnoses like syringomyelia/syringobulbia with Chiari malformation are considered.
Area of Science:
- Neurology
- Medical History
Background:
- Jacqueline du Pré's career ended at 28, attributed to multiple sclerosis (MS).
- MS is an immune-mediated demyelinating disease of the central nervous system.
- Her diagnosis in 1973 was based on progressive neurological symptoms.
Discussion:
- Du Pré's symptoms, including ascending progression and cranial nerve involvement, deviate from typical MS patterns.
- Steroid dependency and potential absence of Uhthoff phenomenon challenge the MS diagnosis.
- Limited radiological confirmation in her era necessitates re-evaluation.
Key Insights:
- The pattern of du Pré's neurological decline suggests an ascending progression, atypical for MS.
- Unusual clinical features, including steroid responsiveness, warrant consideration of alternative diagnoses.
- Reconsidering the diagnosis is crucial given the available historical medical information.
Outlook:
- Syringomyelia/syringobulbia associated with Chiari malformation type I and obstructive hydrocephalus are proposed as alternative diagnoses.
- Further investigation into historical medical records could clarify the etiology of her condition.
- This case highlights the importance of differential diagnosis in complex neurological presentations.
Related Concept Videos
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

